Translational Development Acquisition (TDAC) Cash from Financing Activities (2024 - 2026)

Translational Development Acquisition has reported Cash from Financing Activities for 3 years, with the latest figure at $300000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $175.8 million (changed N/A YoY), and the FY2025 full-year result was $200000.0, down 99.89% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $300000.0, up from $100000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $175.3 million in Q4 2024, with the low at $100000.0 in Q4 2025.
• Historically, Cash from Financing Activities has averaged $44.0 million across 3 years, with a median of $246250.0 in 2024.
• The largest YoY upside for Cash from Financing Activities was 99.94% in 2025 against a maximum downside of 99.94% in 2025.
• Translational Development Acquisition's Cash from Financing Activities stood at $175.3 million in 2024, then plunged by 99.94% to $100000.0 in 2025, then surged by 200.0% to $300000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $300000.0 (Q1 2026), $100000.0 (Q4 2025), and $175.3 million (Q4 2024), per Business Quant data.